EPO is a Berlin-based preclinical contract research organization (CRO) that specializes in oncology and immuno-oncology. Since its founding in 1997, EPO has combined over 25 years of scientific expertise with a strong commitment to translational cancer research.

EPO serves clients worldwide and offers customized, high-quality preclinical services. Its portfolio includes over 1,000 well-characterized patient-derived xenograft (PDX) models, as well as syngeneic and cell line-derived xenograft models. EPO is also recognized for its extensive experience with humanized models, which it has used in studies for over a decade.

EPO is located at the Research Campus Berlin-Buch and operates over 1,300 m² of laboratory space. It employs around 50 professionals, including a highly qualified scientific team.